FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2132596019> ?p ?o ?g. }

• W2132596019 endingPage "8764" @default.
• W2132596019 startingPage "8757" @default.
• W2132596019 abstract "The epidermal growth factor receptor (EGFR) and cyclin D1 are overexpressed in lung carcinogenesis. The rexinoid, bexarotene, represses cyclin D1 and EGFR expression in vitro. It was hypothesized that combining bexarotene with the EGFR inhibitor, erlotinib, would augment clinical activity.In vitro studies and a phase I clinical trial were performed. Twenty-four patients with advanced aerodigestive tract cancers were enrolled; 79% had non-small-cell lung cancer (NSCLC). The primary objective was to determine the maximum-tolerated dose. Clinical activity was a secondary objective.Combining erlotinib with bexarotene enhanced growth suppression in vitro compared with each single-agent treatment. This cooperatively repressed cyclin D1 expression. Clinically, the most frequent toxicities were mild hypertriglyceridemia and skin rash. Two serious treatment-related adverse events occurred (creatine phosphokinase elevation attributed to antilipid therapy and a case of generalized pain). Five objective responses (four partial and one minor) were observed in NSCLC patients. Responses were observed in males and smokers. EGFR sequence analyses did not reveal activating mutations in tumors from assessable responding patients. Median time to progression was 2.0 months; overall survival time was 14.1 months; and 1-year survival rate was 73.8%.The recommended phase II doses are erlotinib 150 mg/d and bexarotene 400 mg/m2/d orally. These agents can be administered in combination at the recommended single-agent doses without added toxicity. Overall survival and clinical features of responding patients differ from prior reports of single-agent erlotinib treatment. These findings are encouraging and warrant further investigation of this regimen." @default.
• W2132596019 created "2016-06-24" @default.
• W2132596019 creator A5002624516 @default.
• W2132596019 creator A5017932012 @default.
• W2132596019 creator A5020397680 @default.
• W2132596019 creator A5051036544 @default.
• W2132596019 creator A5052728393 @default.
• W2132596019 creator A5078795100 @default.
• W2132596019 creator A5083305798 @default.
• W2132596019 creator A5091028729 @default.
• W2132596019 date "2005-12-01" @default.
• W2132596019 modified "2023-10-04" @default.
• W2132596019 title "Bexarotene and Erlotinib for Aerodigestive Tract Cancer" @default.
• W2132596019 cites W1899283284 @default.
• W2132596019 cites W1946563447 @default.
• W2132596019 cites W1977477483 @default.
• W2132596019 cites W1985059561 @default.
• W2132596019 cites W1985980540 @default.
• W2132596019 cites W2000707284 @default.
• W2132596019 cites W2021658870 @default.
• W2132596019 cites W2036223010 @default.
• W2132596019 cites W2040347441 @default.
• W2132596019 cites W2043696829 @default.
• W2132596019 cites W2047670432 @default.
• W2132596019 cites W2049484790 @default.
• W2132596019 cites W2058680827 @default.
• W2132596019 cites W2075121435 @default.
• W2132596019 cites W2077945404 @default.
• W2132596019 cites W2082721939 @default.
• W2132596019 cites W2108885325 @default.
• W2132596019 cites W2111693820 @default.
• W2132596019 cites W2112263503 @default.
• W2132596019 cites W2120718661 @default.
• W2132596019 cites W2133282712 @default.
• W2132596019 cites W2138047541 @default.
• W2132596019 cites W2138297714 @default.
• W2132596019 cites W2145295538 @default.
• W2132596019 cites W2161821474 @default.
• W2132596019 cites W2285752907 @default.
• W2132596019 cites W2328066855 @default.
• W2132596019 cites W2335445771 @default.
• W2132596019 cites W2415727307 @default.
• W2132596019 cites W2586988269 @default.
• W2132596019 doi "https://doi.org/10.1200/jco.2005.01.9521" @default.
• W2132596019 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16314636" @default.
• W2132596019 hasPublicationYear "2005" @default.
• W2132596019 type Work @default.
• W2132596019 sameAs 2132596019 @default.
• W2132596019 citedByCount "57" @default.
• W2132596019 countsByYear W21325960192012 @default.
• W2132596019 countsByYear W21325960192013 @default.
• W2132596019 countsByYear W21325960192014 @default.
• W2132596019 countsByYear W21325960192015 @default.
• W2132596019 countsByYear W21325960192016 @default.
• W2132596019 countsByYear W21325960192017 @default.
• W2132596019 countsByYear W21325960192018 @default.
• W2132596019 countsByYear W21325960192019 @default.
• W2132596019 countsByYear W21325960192021 @default.
• W2132596019 crossrefType "journal-article" @default.
• W2132596019 hasAuthorship W2132596019A5002624516 @default.
• W2132596019 hasAuthorship W2132596019A5017932012 @default.
• W2132596019 hasAuthorship W2132596019A5020397680 @default.
• W2132596019 hasAuthorship W2132596019A5051036544 @default.
• W2132596019 hasAuthorship W2132596019A5052728393 @default.
• W2132596019 hasAuthorship W2132596019A5078795100 @default.
• W2132596019 hasAuthorship W2132596019A5083305798 @default.
• W2132596019 hasAuthorship W2132596019A5091028729 @default.
• W2132596019 hasConcept C104317684 @default.
• W2132596019 hasConcept C121608353 @default.
• W2132596019 hasConcept C126322002 @default.
• W2132596019 hasConcept C143998085 @default.
• W2132596019 hasConcept C185592680 @default.
• W2132596019 hasConcept C197934379 @default.
• W2132596019 hasConcept C2776256026 @default.
• W2132596019 hasConcept C2778087573 @default.
• W2132596019 hasConcept C2778570526 @default.
• W2132596019 hasConcept C2778820923 @default.
• W2132596019 hasConcept C2779438470 @default.
• W2132596019 hasConcept C2781413609 @default.
• W2132596019 hasConcept C2909325608 @default.
• W2132596019 hasConcept C55493867 @default.
• W2132596019 hasConcept C63932345 @default.
• W2132596019 hasConcept C71924100 @default.
• W2132596019 hasConcept C86339819 @default.
• W2132596019 hasConcept C90924648 @default.
• W2132596019 hasConcept C98274493 @default.
• W2132596019 hasConceptScore W2132596019C104317684 @default.
• W2132596019 hasConceptScore W2132596019C121608353 @default.
• W2132596019 hasConceptScore W2132596019C126322002 @default.
• W2132596019 hasConceptScore W2132596019C143998085 @default.
• W2132596019 hasConceptScore W2132596019C185592680 @default.
• W2132596019 hasConceptScore W2132596019C197934379 @default.
• W2132596019 hasConceptScore W2132596019C2776256026 @default.
• W2132596019 hasConceptScore W2132596019C2778087573 @default.
• W2132596019 hasConceptScore W2132596019C2778570526 @default.
• W2132596019 hasConceptScore W2132596019C2778820923 @default.
• W2132596019 hasConceptScore W2132596019C2779438470 @default.
• W2132596019 hasConceptScore W2132596019C2781413609 @default.

• next